Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: Early and long-term effects in a pig kidney model

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 3, 2007, Pages

  Jayle, Christophe ^a   Favreau, Frederic ^a   Zhang, Kequiang ^a   Doucet, Carole ^a   Goujon, Jean Michel ^a   Hebrard, William ^b   Carretier, Michel ^a   Eugene, Michel ^a   Mauco, Gerard ^a   Tillement, Jean Paul ^c   Hauet, Thierry ^a,b,d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Institut National de la Recherche Agronomique   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d University of Poitiers   (France)

Author keywords

Ischemia reperfusion injury; Mitochondrial damage; Renal regeneration; Stathmin

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; STATHMIN; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY PERFUSION; KIDNEY TUBULE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REPERFUSION INJURY; TISSUE INJURY; WESTERN BLOTTING;

EID: 33847780459     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00338.2006     Document Type: Article

References (45)

1. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, Ovize M. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 39: 893-899, 2005.
2. Basile DP, Donohoe DL, Roethe K, Mattson DL. Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol Renal Physiol 284: F338-F348, 2003.
3. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 14: 2199-2210, 2003.
4. Brook NR, Waller JR, Nicholson ML. Nonheart-beating kidney donation: current practice and future developments. Kidney Int 63: 1516-1529, 2003.
5. Burne-Taney MJ, Rabb H. The role of adhesion molecules and T cells in ischemic renal injury. Curr Opin Nephrol Hypertens 12: 86-90, 2003.
6. Burne-Taney MJ, Yokota N, Rabb H. Persistent renal and extrarenal immune changes after severe ischemic injury. Kidney Int 67: 1001-1009, 2005.
7. Chaudhri G, Clark IA, Hunt NH, Cowden WB, Ceredig R. Effect of antioxidants on primary alloantigen-induced T cell activation and proliferation. J Immunol 137: 2648-2652, 1986.
8. Domanski L, Sulikowski T, Safranov K, Pawlik A, Olszewska M, Chlubek D, Urasinska E, Ciechanowski K. Effect of trimetazidine on the nucleotide profile in rat kidney with ischemia-reperfusion injury. Eur J Pharm Sci 27: 320-327, 2006.
9. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone KB, Lucien A, Feuvray D. Changes in intracellular sodium and pH during ischemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischemia. Cardiovasc Res 47: 688-696, 2000.
10. Elimadi A, Settaf A, Morin D, Sapena R, Lamchouri F, Cherrah Y, Tillement JP. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 286: 23-28, 1998.
11. Faure JP, Baumert H, Han Z, Goujon JM, Favreau F, Dutheil D, Petit I, Barriere M, Tallineau C, Tillement JP, Carretier M, Mauco G, Papadopoulos V, Hauet T. Evidence for a protective role of trimetazidine during cold ischemia: targeting inflammation and nephron mass. Biochem Pharmacol 66: 2241-2250, 2003.
12. Faure JP, Petit I, Zhang K, Dutheil D, Doucet C, Favreau F, Eugene M, Goujon JM, Tillement JP, Mauco G, Vandewalle A, Hauet T. Protective roles of polyethylene glycol and trimetazidine against cold ischemia and reperfusion injuries of pig kidney graft. Am J Transplant 4: 495-504, 2004.
13. Goujon JM, Hauet T, Menet E, Levillain P, Babin P, Carretier M. Histological evaluation of proximal tubule cell injury in isolated perfused pig kidneys exposed to cold ischemia. J Surg Res 82: 228-233, 1999.
14. Hauet T, Goujon JM, Baumert H, Petit I, Carretier M, Eugene M, Vandewalle A. Polyethylene glycol reduces the inflammatory injury due to cold ischemia/reperfusion in autotransplanted pig kidneys. Kidney Int 62: 654-667, 2002.
15. Hauet T, Goujon JM, Vandewalle A, Baumert H, Lacoste L, Tillement JP, Eugene M, Carretier M. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol 11: 138-148, 2000.
16. Hauet T, Baumert H, Amor IB, Gibelin H, Tallineau C, Eugene M, Tillement JP, Carretier M. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine. J Pharmacol Exp Ther 292: 254-260, 2000.
17. Heinzelmann M, Mercer-Jones MA, Passmore JC. Neutrophils and renal failure. Am J Kidney Dis 34: 384-399, 1999.
18. Jassem W, Fuggle SV, Rela M, Koo DD, Heaton ND. The role of mitochondria in ischemia/reperfusion injury. Transplantation 73: 493-499, 2002.
19. Junqueira L, Bignoles G, Brentani R. Picro Sirius staining plus polarization microscopic, a specific method for collagen detection in tissue sections. Histochem J 11: 447-455, 1979.
20. Kantor P, Lucien A, Kozak R, Lopaschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588, 2000.
21. Koppel J, Loyer P, Maucuer A, Rehak P, Manceau V, Guguen-Guillouzo C, Sobel A. Induction of stathmin expression during liver regeneration. FEBS Lett 331: 65-70, 1993.
22. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282: C227-C241, 2002.
23. Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 19: 661-672, 2003.
24. Maupoil V, Rochette L, Tabard A, Clauser P, Harpey C. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv Exp Med Biol 264: 373-376, 1990.
25. Morillas Blasco PJ, Hernándiz Martinez A, Azorín Villena I, Portolés Sanz M, Pallarés Carratalá V, Bertomeu Martínez V, Capdevilla Carbonell C, Aguilar Llopis A, Cosín Aguilar J. Mitochondrial changes induced by trimetazidine in the myocardium. Med Sci Monit 11: 162-167, 2005.
26. Newaz MA, Oyekan AO. Vascular response to endothelin-1, angiotensin-II and U46619 in glycerol-induced acute renal failure. J Cardiovasc Pharmacol 38: 569-577, 2001.
27. Ortiz A, Justo P, Sanz A, Lorz C, Egido J. Targeting apoptosis in acute tubular injury. Biochem Pharmacol 66: 1589-1594, 2003.
28. Ozden A, Aybek Z, Saydam N, Calli N, Saydam O, Duscan E, Guner G. Cytoprotective effect of trimetazidine on 75 min warm ischemia-reperfusion injury in rats. Eur Surg Res 30: 227-234, 1998.
29. Penfield JG, Wang Y, Li S, Kielar MA, Sicher SC, Jeyarajah DR, Lu CY. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney. Kidney Int 56: 1759-1769, 1999.
30. Rowlands DC, Williams A, Jones NA, Guest SS, Reynolds GM, Barber PC, Brown G. Stathmin expression in a feature of proliferating cells of most, if not all, cell lineages. Lab Invest 72: 100-113, 1995.
31. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biol 93: 242-250, 2004.
32. Ruiz-Meana M, Garcia-Dorado D, Julia M, Gonzalez MA, Inserte J, Soler-Soler J. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 32: 587-592, 1996.
33. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 175: 153-162, 1997.
34. Siegel NJ, Shah SV. Acute renal failure: directions for the next decade. J Am Soc Nephrol 14: 2176-2177, 2003.
35. 2. Free Radic Biol Med 30: 1357-1364, 2001.
36. Vetterlein F, Petho M, Schmidt G. Distribution of capillary blood flow in rat kidney during postischemic renal failure. Am J Physiol 20: 510-519, 1986.
37. Villanueva S, Cespedes, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 290: R861-R870, 2006.
38. Williams FM, Tanda K, Kus M, Wiliams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 22: 828-833, 1993.
39. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 93: 2175-2188, 1994.
40. Yin RX, Liang WW, Liu TW, Tao XZ, Zhu LG, Al-Ghazali R. Inhibitory effect of trimetazidine on cardiac myocyte apoptosis in rabbit model of ischemia-reperfusion (Abstract). Chin Med Sci 19: 242, 2004.
41. Ysebaert DK, De Greef KE, Vercauteren SR, Ghielli M, Verpooten GA, Eyskens EJ, De Broe ME. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant 15: 1562-1574, 2000.
42. Ysebaert DK, De Greef KE, De Beuf A, Van Rompay AR, Vercauteren S, Persy VP, De Broe ME. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int 66: 491-496, 2004.
43. Yukselen V, Karaoglu AO, Yenisey C, Tuncyurek M, Ozutemiz O. Trimetazidine reduces the degree of fibrosis in alkali burns of the esophagus. J Pediatr Surg 40: 505-509, 2005.
44. Zahedi K, Wang Z, Barone S, Tehrani K, Yokota N, Petrovic S, Rabb H, Soleimani M. Identification of stathmin as a novel marker of cell proliferation in the recovery phase of acute ischemic renal failure. Am J Physiol Cell Physiol 286: C1203-C1211, 2004.
45. Zahedi K, Revelo MP, Barone S, Wang Z, Tehrani K, Citron DP, Bissler JJ, Rabb H, Soleimani M. Stathmin-deficient mice develop fibrosis and show delayed recovery from ischemic-reperfusion injury. Am J Physiol Renal Physiol 290: F1559-F1567, 2006.